Medgenics Reports Second Quarter Financial Results

WAYNE, Pa. and MISGAV, Israel, July 16, 2014 (GLOBE NEWSWIRE) — Medgenics, Inc. (NYSE MKT:MDGN) (the Company), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today reported financial results for the three and six months ended June 30, 2014 and the filing with the U.S. Securities and Exchange Commission (SEC) of the Company’s Quarterly Report on Form 10-Q. The Form 10-Q includes unaudited interim consolidated financial statements containing the information presented below, as well as additional information regarding the Company. The Form 10-Q is available at www.sec.govand at

This entry was posted in Recent Development News: Q3 – 2014. Bookmark the permalink.